Alvarez C, Cremades N, Blasco N, Bernabeu R
Bernabeu Institute, Fertility and Gynecology, Alicante, Spain.
Hum Reprod. 1997 Nov;12(11):2366-9. doi: 10.1093/humrep/12.11.2366.
The goal of our study was to assess whether the total dose of gonadotrophin-releasing hormone agonist (GnRHa) administered affects the success of an in-vitro fertilization (IVF) programme. A retrospective analysis was performed on a total of 72 IVF cycles carried out on 70 patients with different causes of infertility included in our assisted reproduction programme. Cycles were divided into two groups according to the number of days of GnRHa administration (leuprolide acetate 1 mg/day) necessary until ovarian desensitization occurred: group I (GI) < 13 days (n = 27) and group II (GII) > or = 13 days (n = 45). The following parameters were assessed: number of gonadotrophin ampoules, number of stimulation days, endometrial thickness on the day of human chorionic gonadotrophin (HCG) administration, number of recovered oocytes, pregnancy rate. Pregnancy rate/cycle and pregnancy rate/transfer were positively correlated with the dose of GnRHa (GI: 44 and 60% respectively versus GII: 20% and 25% respectively). It is concluded that a long administration of GnRHa has no effect upon ovarian response, although the pregnancy rate is subsequently decreased.
我们研究的目的是评估促性腺激素释放激素激动剂(GnRHa)的给药总剂量是否会影响体外受精(IVF)方案的成功率。对纳入我们辅助生殖方案的70例不同原因不孕症患者进行的总共72个IVF周期进行了回顾性分析。根据发生卵巢脱敏所需的GnRHa给药天数(醋酸亮丙瑞林1mg/天)将周期分为两组:第一组(GI)<13天(n = 27)和第二组(GII)≥13天(n = 45)。评估了以下参数:促性腺激素安瓿数量、刺激天数、人绒毛膜促性腺激素(HCG)给药当天的子宫内膜厚度、回收的卵母细胞数量、妊娠率。周期妊娠率和移植妊娠率与GnRHa剂量呈正相关(GI组分别为44%和60%,而GII组分别为20%和25%)。得出的结论是,GnRHa的长期给药对卵巢反应没有影响,尽管随后妊娠率会降低。